Teladoc Health (NYSE:TDOC) Stock Gets Price Target Increase from UBS Group

Teladoc Health (NYSE:TDOC) had its price target lifted by UBS Group from $6.50 to $9.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage currently has a “neutral” rating on the health services provider’s stock. UBS Group‘s price objective points to a potential upside of 4.35% from the stock’s current price.

A number of other research analysts have also commented on the stock. Stifel Nicolaus lifted their price objective on shares of Teladoc Health from $5.50 to $6.50 and gave the company a “hold” rating in a research note on Thursday. Canaccord Genuity Group lowered their price target on Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Argus cut Teladoc Health from a “hold” rating to a “sell” rating in a research report on Monday. Oppenheimer upped their price objective on Teladoc Health from $7.00 to $10.00 and gave the company an “outperform” rating in a research note on Monday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teladoc Health in a research report on Wednesday, August 19th. Five analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Teladoc Health has a consensus rating of “Hold” and an average target price of $8.07.

Teladoc Health Stock Up 1.4%

TDOC traded up $0.12 during trading on Monday, hitting $8.62. 6,061,988 shares of the stock were exchanged, compared to its average volume of 5,110,268. The firm has a market capitalization of $1.57 billion, a P/E ratio of -10.03 and a beta of 2.00. Teladoc Health has a 1-year low of $4.40 and a 1-year high of $9.89. The stock has a fifty day moving average price of $6.23 and a two-hundred day moving average price of $6.47.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, October 28th. The health services provider reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. The business had revenue of $605.10 million for the quarter, compared to analyst estimates of $588.14 million. Teladoc Health had a negative net margin of 6.27% and a negative return on equity of 11.63%. The company’s revenue for the quarter was down 3.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.28) earnings per share. Analysts predict that Teladoc Health will post -0.89 EPS for the current year.

Insider Activity

In related news, CEO Charles III sold 17,805 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $6.10, for a total transaction of $108,610.50. Following the sale, the chief executive officer owned 465,535 shares of the company’s stock, valued at $2,839,763.50. This trade represents a 3.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.70% of the stock is owned by corporate insiders.

Institutional Trading of Teladoc Health

Hedge funds have recently bought and sold shares of the company. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Teladoc Health during the second quarter valued at approximately $1,447,000. Counterpoint Mutual Funds LLC grew its stake in Teladoc Health by 1,017.4% during the third quarter. Counterpoint Mutual Funds LLC now owns 1,650,165 shares of the health services provider’s stock worth $9,571,000 after buying an additional 1,502,488 shares during the period. Monaco Asset Management SAM acquired a new stake in shares of Teladoc Health in the second quarter worth $26,864,000. ABS Investment Management LLC acquired a new stake in shares of Teladoc Health in the second quarter worth $1,513,154. Finally, ABS Direct Equity Fund LLC purchased a new position in shares of Teladoc Health in the 2nd quarter valued at $1,513,000. Institutional investors and hedge funds own 76.82% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.